Combination chemotherapy in disseminated melanoma and other solid tumors in adults.
Eighty-eight patients with disseminated melanoma and 22 patients with various other solid tumors were treated with combination chemotherapy consisting of DTIC, at a fixed dose, with either adriamycin, CCNU, or hydroxyurea, at several dosages.  An objective response rate of 20% was observed in 84 evaluable melanoma patients.  The addition of the other agents to DTIC did not provide enhanced antitumor activity.  Combination chemotherapy increased toxicity.  Encouraging objective responses were observed in patients with synovial sarcoma (4/7) and teratocarcinoma of the testis (1/1) treated with the combination of adriamycin and DTIC.
D002986:Clinical Trials as Topic; D003606:Dacarbazine / Q000627:therapeutic use* / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000627:therapeutic use* / Q000633:toxicity; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D008130:Lomustine / Q000627:therapeutic use* / Q000633:toxicity; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality; D009369:Neoplasms / Q000188:drug therapy / Q000401:mortality; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D014226:Triazenes / Q000627:therapeutic use*
D009607:Nitrosourea Compounds; D014226:Triazenes; D008130:Lomustine; D003606:Dacarbazine; D004317:Doxorubicin